- Home
- MEOH vs RARE Comparison
MEOH vs RARE Comparison
Compare MEOH & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEOH
- RARE
- Stock Information
- Founded
- MEOH 1968
- RARE 2010
- Country
- MEOH Canada
- RARE United States
- Employees
- MEOH N/A
- RARE 1294
- Industry
- MEOH Major Chemicals
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- MEOH Industrials
- RARE Health Care
- Exchange
- MEOH Nasdaq
- RARE Nasdaq
- Market Cap
- MEOH 3.0B
- RARE 3.0B
- IPO Year
- MEOH N/A
- RARE 2014
- Fundamental
- Price
- MEOH $35.95
- RARE $31.90
- Analyst Decision
- MEOH Buy
- RARE Strong Buy
- Analyst Count
- MEOH 9
- RARE 14
- Target Price
- MEOH $46.89
- RARE $86.64
- AVG Volume (30 Days)
- MEOH 479.3K
- RARE 1.7M
- Earning Date
- MEOH 11-05-2025
- RARE 11-04-2025
- Dividend Yield
- MEOH 1.98%
- RARE N/A
- EPS Growth
- MEOH 62.76
- RARE N/A
- EPS
- MEOH 3.48
- RARE N/A
- Revenue
- MEOH $3,576,740,000.00
- RARE $610,159,000.00
- Revenue This Year
- MEOH $7.67
- RARE $19.72
- Revenue Next Year
- MEOH $9.36
- RARE $23.29
- P/E Ratio
- MEOH $10.75
- RARE N/A
- Revenue Growth
- MEOH N/A
- RARE 26.77
- 52 Week Low
- MEOH $25.46
- RARE $25.81
- 52 Week High
- MEOH $54.49
- RARE $58.00
- Technical
- Relative Strength Index (RSI)
- MEOH 40.52
- RARE 59.32
- Support Level
- MEOH $36.04
- RARE $30.95
- Resistance Level
- MEOH $41.35
- RARE $32.30
- Average True Range (ATR)
- MEOH 1.27
- RARE 1.18
- MACD
- MEOH -0.54
- RARE 0.26
- Stochastic Oscillator
- MEOH 0.74
- RARE 91.21
About MEOH Methanex Corporation
Methanex Corp manufactures and sells methanol. Its customers use methanol as a feedstock to produce end-products including adhesives, foams, solvents, and windshield washer fluids. The firm also sells its products to the oil refining industry, where the methanol is blended with gasoline to produce a high-octane fuel or blended as a component of biodiesel. It distributes its products through an extensive supply chain that includes the operation of port terminals, tankers, barges, rail cars, trucks, and pipelines. The company generates the majority of its revenue from Europe.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.